Kai Pharmaceuticals, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
9
Ending by 2030
Jan 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Aug 9, 2027The maintenance fee for Modifications of peptide compositions to increase stability and delivery efficiency (US 9,255,124) comes due Aug 9, 2027. Unpaid by Feb 9, 2028, it lapses early.
- 1 fee due Sep 8, 2027The maintenance fee for Therapeutic agents for reducing parathyroid hormone levels (US 9,278,995) comes due Sep 8, 2027. Unpaid by Mar 8, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,077,438 | Modifications of peptide compositions to increase stability and delivery efficiency In force · From the USPTO record | In force | From the USPTO record | |
| US 8,067,532 | Modifications of peptide compositions to increase stability and delivery efficiency In force · From the USPTO record | In force | From the USPTO record | |
| US 8,987,200 | Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders In force · From the USPTO record | In force | From the USPTO record | |
| US 9,255,124 | Modifications of peptide compositions to increase stability and delivery efficiency In force · From the USPTO record | In force | From the USPTO record | |
| US 8,377,880 | Therapeutic agents for reducing parathyroid hormone levels In force · From the USPTO record | In force | From the USPTO record | |
| US 9,567,370 | Therapeutic agents for reducing parathyroid hormone levels In force · From the USPTO record | In force | From the USPTO record | |
| US 9,701,712 | Therapeutic agents for reducing parathyroid hormone levels In force · From the USPTO record | In force | From the USPTO record | |
| US 10,280,198 | Therapeutic Agents for Reducing Parathyroid Hormone Levels In force · Medium confidence | In force | Medium confidence | |
| US 9,278,995 | Therapeutic agents for reducing parathyroid hormone levels In force · From the USPTO record | In force | From the USPTO record | |
| US 8,999,932 | Therapeutic Agents for Reducing Parathyroid Hormone Levels In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 11: 15 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 abandoned · 15 no status recorded